New eczema drug cibinqo under Real-World safety review in korea
NCT ID NCT05391061
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 29 times
Summary
This study is checking how safe and effective the drug Cibinqo (abrocitinib) is for people with moderate to severe atopic dermatitis, a type of eczema. About 1,100 participants in Korea will take the tablet by mouth and be followed for one year. Researchers will track side effects and how well the drug clears the skin rash.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DERMATITIS, ATOPIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Pfizer Tower
RECRUITINGSeoul, 04631, South Korea
Conditions
Explore the condition pages connected to this study.